In vivo pharmacokinetics and toxicity profile of the anti-HIV agent stampidine in dogs and feline immunodeficiency virus-infected cats

Arzneimittel-Forschung/Drug Research

Volumn 56, Issue 2 A, 2006, Pages 176-192

  Uckun, Fatih M ^a,b,c   Waurzyniak, Barbara ^a,b   Tibbies, Heather ^a,b   Venkatachalam, Taracad K ^a,b   Erbeck, Doug ^a,b  

^a PARKER HUGHES INSTITUTE   (United States)

^b Paradigm Pharmaceuticals   (United States)

^c Ikaros Enterprises   (United States)

Author keywords

Anti HIV agents; Antiretroviral therapy; CAS 217178 62 6; DDE 113; HI 113; N p (4 Bromophenyl) 2',3' didehydro 3' deoxy 5' thymidylyl L alanine methyl ester; Stampidine, toxicity profile

Indexed keywords

ALANINE AMINOTRANSFERASE; CAS 217178 62 6; CAS 3056 17 5; DDE 113; DIDANOSINE; DOLASETRON MESILATE; HI 113; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAMPIDINE; STAVUDINE; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL TISSUE; ARTICLE; CAT; DOG; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; FELINE IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IC 50; MALE; NAUSEA; NONHUMAN; TOXICITY TESTING; VIRUS INFECTION; VOMITING;

EID: 33645096955     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296805     Document Type: Article

References (34)

1. Albrecht, M. A., Bosch, R. J., Hammer, S. M. et al., Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. N. Engl. J. Med. 345, 398 (2001)
2. Freedberg, K. A., Losina, E., Weinstein, M. C. et al., The cost effectiveness of combination antiretroviral therapy for HIV disease. N. Engl. J. Med. 344, 824 (2001)
3. Rey, D., Schmitt, M. P., Partisani, M. et al., Efavirenz as a substitute for protease inhibitors in HIV-1-infected patients with undetectable plasma viral load on HAART: a median follow-up of 64 weeks. J. Acquir. Immune Defic. Syndr. 27, 459 (2001)
4. Starr, S. E., Fletcher, C. V., Spector, S. A. et al., Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team. N. Engl. J. Med. 341, 1874 (1999)
5. Lerma, J. G., Heneine, W., Resistance of human immunodeficiency virus type 1 to reverse transcriptase and protease inhibitors: genotypic and phenotypic testing. J. Clin. Virol. 21, 197 (2001)
6. O'Brien, W. A., Resistance against reverse transcriptase inhibitors. Clin. Infect. Dis. 30 (Suppl. 2), S185 (2000)
7. Pillay, D., Taylor, S., Richman, D. D., Incidence and impact of resistance against approved antiretroviral drugs. Rev. Med. Virol. 10, 231 (2000)
8. Venturi, G., Romano, L., Catucci, M. et al., Genotypic resistance to zidovudine as a predictor of failure of subsequent therapy with human immunodeficiency virus type-1 nucleoside reverse-transcriptase inhibitors. Eur. J. Clin. Microbiol. Infect. Dis. 18, 274 (1999)
9. Richman, D. D., HIV chemotherapy. Nature 410, 995 (2001)
10. Uckun, F. M., Vig, R., US Patent No. 6,030,957, Aryl phosphate derivatives of d4T having anti-HIV activity (2/29/ 2000)
11. Uckun, F. M., Vig, R., US Patent No. 6,350,736, Aryl phosphate derivatives of d4T having anti-HIV activity (2/26/ 2002)
12. Uckun, F. M., US Patent No. 6,503,890, Aryl phosphate derivatives of d4T having anti-HIV activity (1/7/2003)
13. Uckun, F. M., Vig, R., US Patent No. 6,528,495, Aryl phosphate derivatives of d4T having anti-HIV activity (3/4/ 2003)
14. Uckun, F. M., Vig, R., US Patent No. 6,537,975, Aryl phosphate derivatives of d4T having anti-HIV activity (3/25/ 2003)
15. Uckun, F. M., Vig, R., US Patent No. 6,670,336, Aryl phosphate derivatives of d4T having anti-HIV activity (12/30/ 2003)
16. Uckun, F. M., Vig, R., US Patent Application Publication US 2004/0171577 Al, Aryl phosphate derivatives of d4T having anti-HIV activity (9-2-04)
17. Uckun, F. M., Vig, R., European Patent Specification EP 1090018 B1, Aryl phosphate derivatives of d4T having anti-HIV activity
18. Venkatachalam, T. K., Tai, H. L., Vig, R. et al., Enhancing effects of a mono-bromo substitution at the para position of the phenyl moiety on the metabolism and anti-HIV activity of d4T-phenyl methoxyalaninyl phosphate derivatives. Bioorg. Med. Chem. Lett. 8, 3121 (1998)
19. Uckun, F. M., Pendergrass, S., Qazi, S. et al., Phenyl phosphoramidate derivatives of STV as anti-HIV agents with potent and selective in-vitro antiviral activity against adenovirus. Eur. J. Med. Chem. 39, 225 (2004)
20. Vig, R., Venkatachalam, T. K., Uckun, F. M., D4T-5′-[p-bromophenyl methoxyalaninyl phosphate] as a potent and non-toxic anti-human immunodeficiency virus agent. Antivir. Chem. Chemother. 9, 445 (1998)
21. Uckun, F. M., Pendergrass, S., Venkatachalam, T. K. et al., STAMP is a potent inhibitor of Zidovudine- and nucleoside analog reverse transcriptase inhibitor-resistant primary clinical human immunodeficiency virus type 1 isolates with thymidine analog mutations. Antimicrob Agents Chemother. 46, 3613 (2002)
22. Uckun, F. M., Pendergrass, S., Qazi, S. et al., In vitro activity of STAMP against primary clinical human immunodeficiency virus isolates. Arzneim.-Forsch./Drug Res. 54, 69 (2004)
23. Chen, C. L., Venkatachalam, T. K., Zhu, Z. H. et al., In vivo pharmacokinetics and metabolism of anti-human immunodeficiency virus agent D4T-5'-[p-bromophenyl methoxyalaninyl phosphate] (sampidine) in mice. Drug Metab. Dispos. 29, 1035 (2001)
24. Chen, C. L., Yu, G., Venkatachalam, T. K. et al., Metabolism of STV-5'-[p-bromophenyl methoxyalaninyl phosphate], STAMP, in mice, dogs, and cats. Drug Metab. Dispos. 30, 1523 (2002)
25. Uckun, F. M., Qazi, S., Pendergrass, S. et al., In vivo toxicity, pharmacokinetics, and anti-human immunodeficiency virus activity of STV-5'-(p-bromophenyl methoxyalaninyl phosphate) (STAMP) in mice. Antimicrob Agents Chemother. 46, 3428 (2002)
26. Uckun, F. M., Chen, C. L., Lisowski, E. et al., Toxicity and pharmacokinetics of STAMP in mice and rats. Arzneim.-Forsch./Drug Res. 53, 357 (2003)
27. D'Cruz, O. J., Uckun, F. M., Clinical development of microbicides for the prevention of HIV infection. Curr. Pharm. Des. 10, 315 (2004)
28. D'Cruz, O. J., Uckun, F. M., STAMP is a potential non-spermicidal broad-spectrum anti-human immunodeficiency virus microbicide. Fertil. Steril. 81 (Suppl. 1), 831 (2004)
29. D'Cruz, O. J., Samuel, P., Waurzyniak, B. et al., Development and evaluation of a thermoreversible ovule formulation of STAMP, a novel nonspermicidal broad-spectrum anti-human immunodeficiency virus microbicide. Biol. Reprod. 69, 1843 (2003)
30. Uckun, F. M., Petkevich, A. S., Vassilev, A. O. et al., STAMP prevents mortality in an experimental mouse model of viral hemorrhagic fever caused by LCMV In preparation
31. Uckun, F. M., Petkevich, A. S., Vassilev, A. O. et al., STAMP prevents mortality in an experimental mouse model of viral hemorrhagic fever caused by lassa virus. BioMed Central Infect. Dis. 4, 1 (2004)
32. Uckun, E, Qazi, S., Venkatachalam, T., In vitro anti-HIV potency of stapidine alone and in combination with standard anti-HIV drugs. Arzneim.-Forsch./Drug Res. 55, 223 (2005)
33. Gabrielsson, J., Weiner, D., Pharmacokinetic/Pharmacodynamic Data Analysis: Concepts and Applications. Swedish Pharmaceutical Press (1997)
34. Uckun, F. M., Chen, C. L., Samuel, P., et al., In vivo antiretroviral activity of stampidine in chronically feline immunodeficiency virus-infected cats. Antimicrob. Agents Chemother. 47, 1233 (2003)